Targeting the kallikrein-kinin system as a new therapeutic approach to diabetic retinopathy

Current Opinion in Investigational Drugs

Volumn 11, Issue 5, 2010, Pages 507-514

  Pruneau, Didier ^a   Bélichard, Pierre ^a   Sahel, José Alain ^b   Combal, Jean Philippe ^a  

^a INSTITUT DE LA VISION   (France)

^b SORBONNE UNIVERSITÉ   (France)

Author keywords

Diabetic retinopathy; Inflammation; Kallikrein kinin system; Kinin B1 receptor; Plasma kallikrein inhibitor; Vascular permeability

Indexed keywords

ACETYLLYSYLBRADYKININ[7 [3 (2 NAPHTHYL)ALANINE] 8 ISOLEUCINE 9 DEARGININE]; ADVANCED GLYCATION END PRODUCT; CHEMOKINE; CORTICOSTEROID; CYTOKINE; FOV 2304; GROWTH FACTOR; ICATIBANT; KALLIKREIN; KALLIKREIN INHIBITOR; MESSENGER RNA; PLASMA KALLIKREIN; RANIBIZUMAB; RECOMBINANT PROTEIN; UNCLASSIFIED DRUG; VASCULOTROPIN INHIBITOR;

BLINDNESS; BLOOD VESSEL PERMEABILITY; DIABETIC MACULAR EDEMA; DIABETIC RETINOPATHY; GENE EXPRESSION; HUMAN; HYPERGLYCEMIA; INFLAMMATION; INSULIN DEPENDENT DIABETES MELLITUS; KALLIKREIN KININ SYSTEM; LEUKOCYTE ADHERENCE; LOW LEVEL LASER THERAPY; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; RETINA BLOOD VESSEL; RETINA HEMORRHAGE; RETINA MACULA EDEMA; RETINA NEOVASCULARIZATION; REVIEW; VISUAL IMPAIRMENT; VITREOUS BODY;

ANIMALS; CAPILLARY PERMEABILITY; DIABETES MELLITUS, EXPERIMENTAL; DIABETIC RETINOPATHY; DRUG DESIGN; ENDOTHELIUM, VASCULAR; HUMANS; KALLIKREIN-KININ SYSTEM; KALLIKREINS; NEOVASCULARIZATION, PATHOLOGIC; RATS; RECEPTOR, BRADYKININ B1; RETINAL VESSELS;

EID: 77952151112     PISSN: 14724472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (57)

1. Diabetes Fact Sheet 312: World Health Organization, Geneva, Switzerland (2009). www.who.int/mediacentre/factsheets/fs312/en.
2. Delcourt C, Massin P, Rosilio M: Epidemiology of diabetic retinopathy: Expected vs reported prevalence of cases in the French population. Diabetes Metab (2009) 35(6):431-438.
3. Congdon NG, Friedman DS, Lietman T: Important causes of visual impairment in the world today. JAMA (2003) 290(15):2057-2060.
4. Hammes HP, Lin J, Renner O, Shani M, Lundqvist A, Betsholtz C, Brownlee M, Deutsch U: Pericytes and the pathogenesis of diabetic retinopathy. Diabetes (2002) 51(10):3107-3112.
5. Wolf S, Massin P, Bandello F, Sharp D, Lanzetta P, Larsen M, Wolf-Snurrbusch U, Gekkieva M: Safety and efficacy of ranibizumab treatment in patients with diabetic macular edema: 12-months results of the resolve study. ARVO 2009, Fort Lauderdale, FL, USA (2009) : Abs 4331.
6. Beck RW, Edwards AR, Aiello LP, Bressler NM, Ferris F, Glassman AR, Hartnett E, Ip MS, Kim JE, Kollman C: Three-year follow-up of a randomized trial comparing focal/grid photocoagulation and intravitreal triamcinolone for diabetic macular edema. Arch Ophthalmol (2009) 127(3):245-251.
7. Moreau ME, Garbacki N, Molinaro G, Brown NJ, Marceau F, Adam A: The kallikrein-kinin system: Current and future pharmacological target. J Pharmacol Sci (2005) 99(1):6-38.
8. Schmaier AH: Assembly, activation, and physiologic infuence of the plasma kallikrein/kinin system. Int Immunopharmacol (2008) 8(2):161-165.
9. Shariat-Madar Z, Mahdi F, Schmaier AH: Identification and characterization of prolylcarboxypeptidase as an endothelial cell prekallikrein activator. J Biol Chem (2002) 277(20):17962-17969. (Pubitemid 34967607)
10. Sainz IM, Pixley RA, Colman RW: Fifty years of research on the plasma kallikrein-kinin system: From protein structure and function to cell biology and in-vivo pathophysiology. Thromb Haemost (2007) 98(1):77-83
11. Leeb-Lundberg LM, Marceau F, Müller-Esterl W, Petitbone DJ, Zuraw BL: International Union of Pharmacology. XLV. Classification of the kinin receptor family: From molecular mechanisms to pathophysiological consequences. Pharmacol Rev (2005) 57(1):27-77.
12. Joussen AM, Poulaki V, Le ML, Koizumi K, Esser C, Janicki A, Schraermeyer U, Kociok N, Fauser S, Kirchhof B, Kern TS et al: A central role for inflammation in the pathogenesis of diabetic retinopathy. FASEB J (2004) 18(12):1450-1452. • Diabetic mice deficient in the genes coding for the leukocyte adhesion molecule ICAM-1 and the integrin ligand CD-18 demonstrated a significant reduction in leukostasis, leakage and damaged endothelial cells in the retinal vasculature at 11 and 15 months. These data highlighted the central role of leukocytes in the pathogenesis of diabetic retinopathy. (Pubitemid 39561611)
13. Garner TW, Antonetti DA: Novel potential mechanisms for diabetic macular edema: Leveraging new investigational approaches. Curr Diab Rep (2008) 8(4):263-269.
14. Li J, Wang JJ, Chen D, Mott R, Yu Q, Ma J-X, Zhang SX: Systemic administration of HMG-CoA reductase inhibitor protects the blood-retinal barrier and ameliorates retinal inflammation in type 2 diabetes. Exp Eye Res (2009) 89(1):71-78.
15. Hughes JM, Brink A, Witmer AN, Hanraads-de Wiemer M, Klaassen I, Schlingemann RO: Vascular leukocyte adhesion molecules unaltered in the human retina in diabetes. Br J Ophthalmol (2004) 88(4):566-572.
16. McLeod DS, Lefer DJ, Merges C, Lutty GA: Enhanced expression of intracellular adhesion molecule-1 and P-selectin in the diabetic human retina and choroid. Am J Pathol (1995) 147(3):642-653. • Provided the first demonstration that an increased number of neutrophils and elevated ICAM-1 expression are present in the retina of individuals with diabetes.
17. MacKinnon JR, Knott RM, Forrester JV: Altered L-selectin expression in lymphocytes and increased adhesion to endothelium in patients with diabetic retinopathy. Br J Ophthalmol (2004) 88(9):1137-1141.
18. Mastej K, Adamiec R: Neutrophil surface expression of CD11b and CD62L in diabetic microangiopathy. Acta Diabetol (2008) 45(3):183-190.
19. Demircan N, Safran BG, Soylu M, Ozcan AA, Sizmaz S: Determination of vitreous interleukin-1 (IL-1) and tumor necrosis factor (TNF) levels in proliferative diabetic retinopathy. Eye (2006) 20(12):1366-1369.
20. Patel JI, Saleh GM, Hykin PG, Gregor ZJ, Cree IA: Concentration of haemodynamic and inflammatory related cytokines in diabetic retinopathy. Eye (2008) 22(2):223-228.
21. Petrovic MG, Korosec P, Kosnik M, Hawlina M: Vitreous levels of interleukin-8 in patients with proliferative diabetic retinopathy. Am J Ophthalmol (2007) 143(1):175-176.
22. Yoshimura T, Sonoda K-H, Sugahara M, Mochizuki Y, Enaida H, Oshima Y, Ueno A, Hata Y, Yoshida H, Ishibashi T: Comprehensive analysis of inflammatory immune mediators in vitreoretinal diseases. PLoS ONE (2009) 4 (12) : e8158.
23. Yuuki T, Kanda T, Kimura Y, Kotajima N, Tamura J, Kobayashi I, Kishi S: Inflammatory cytokines in vitreous fuid and serum of patients with diabetic retinopathy. J Diabetes Complications (2001) 15(5):257-259. (Pubitemid 32750613)
24. Ma J-X, Song Q, Hatcher HC, Crouch RK, Chao L, Chao J: Expression and cellular localization of the kallikrein-kinin system in human ocular tissues. Exp Eye Res (1996) 63(1):19-26. (Pubitemid 26258796)
25. Gao BB, Clermont A, Rook S, Fonda SJ, Srinivasan VJ, Wojtkowski M, Fujimoto JG, Avery RL, Arrigg PG, Bursell SE, Aiello LP et al: Extracellular carbonic anhydrase mediates hemorrhagic retinal and cerebral vascular permeability through prekallikrein activation. Nat Med (2007) 13(2):181-188. •• Extracellular CA-1 and prekallikrein levels were increased in the vitreous of patients with diabetic retinopathy. In diabetic rats, CA-1-induced increases in retinal vascular leakage were mediated by activation of the KKS. This report suggests that inhibition of CA-1 and kallikrein provide a therapeutic opportunity for the treatment of hemorrhagic retinal edema.
26. Liu LB, Xue YX, Liu YH, Wang YB: Bradykinin increases blood-tumor barrier permeability by down-regulating the expression levels of ZO-1, occludin and claudin-5, and rearranging actin cytoskeleton. J Neurosci Res (2008) 86(5):1153-1168.
27. Zhang H, Gu YT, Xue YX: Bradykinin-induced blood-brain tumor barrier permeability increase is mediated by adenosine 5'-triphosphate-sensitive potassium channel. Brain Res (2007) 1144:33-41. (Pubitemid 46440831)
28. Tiruppathi C, Ahmmed GU, Vogel SM, Malik AB: Ca2+ signaling, TRP channels, and endothelial permeability. Microcirculation (2006) 13(8):693-708.
29. Leeb-Lundberg LM, Song XH, Mathis SA: Focal adhesionassociated proteins p125FAK and paxillin are substrates for bradykinin-stimulated tyrosine phosphorylation in Swiss 3T3 cells. J Biol Chem (1994) 269(39):24328-24334.
30. 2 receptor contributes to endothelial nitric-oxide synthase activation in cardiac capillary endothelial cells. J Biol Chem (2002) 277(3):2028-2032.
31. Thuringer D: The vascular endothelial growth factor-induced disruption of gap junctions is relayed by an autocrine communication via ATP release in coronary capillary endothelium. Ann NY Acad Sci (2004) 1030:14-27.
32. Warboys CM, Toh HB, Fraser PA: Role of NADPH oxidase in retinal microvascular permeability increase by RAGE activation. Invest Ophthalmol Vis Sci (2009) 50(3):1319-1328.
33. 2 receptor antagonist, in a rat model of closed head trauma. J Neurotrauma (1999) 16(11):1057-1065.
34. 2 receptor antagonist, reduces intracranial hypertension and histopathological damage after experimental traumatic brain injury. Neurosc Lett (2009) 454(2):115-117.
35. Marceau F, Regoli D: Bradykinin receptor ligands: Therapeutic perspectives. Nat Rev Drug Discov (2004) 3(10):845-852.
36. 2 receptors. Br J Pharmacol (2008) 154(1):136-143.
37. Phipps JA, Clermont AC, Sinha S, Chilcote TJ, Bursell S-E, Feener EP: Plasma kallikrein mediates angiotensin II type 1 receptor-stimulated retinal vascular permeability. Hypertension (2009) 53(2):175-181.
38. 1Rs could be targets for the treatment of diabetic retinopathy.
39. Feener EP: Kallikrein kinin system in diabetic retinopathy. 5th International Symposium Peptide Receptors and Kinin, Québec City, QC, Canada (2009). • Intravitreous injection of recombinant plasma kallikrein induced retinal edema and hemorrhage in diabetic rats, and systemic treatment with a kallikrein inhibitor reduced retinal vascular leakage.
40. 1-kinin receptor expression and signaling in endothelial cells. Biochem Biophys Res Com (2006) 345(2):652-659.
41. 2R act as intermediate signaling molecules in high glucoseinduced stimulation of glutamate uptake in ARPE cells. J Cell Physiol (2009) 221(3):677-687.
42. 1 receptor antagonist. Reg Pept (2005) 124 (1-3) : 221-224.
43. 1 receptor blockade: A promising treatment of diabetic retinopathy. 5th International Symposium Peptide Receptors and Kinin, Québec City, QC, Canada (2009).
44. 1R expression. This result should be considered in perspective with the fnding that IL-1 and IL-8 levels are significantly elevated in the vitreous of patients with diabetic retinopathy.
45. 1 receptor up-regulation after lipopolysaccharide administration: Role of proinflammatory cytokines and neutrophil infux. J Immunol (2004) 172(3):1839-1847.
46. Zhang J, Gerhardinger C, Lorenzi M: Early complement activation and decreased level of glycosylphosphatidylinositolanchored complement inhibitors in human and experimental diabetic retinopathy. Diabetes (2002) 51(12):3499-3504.
47. Bossi F, Fischetti F, Pellis V, Bulla R, Ferrero E, Mollnes TE, Regoli D, Tedesco F: Platelet-activating factor and kinin-dependent vascular leakage as a novel functional activity of the soluble terminal complement complex. J Immunol (2004) 173(11):6921-6927.
48. Adamis AP, Berman AJ: Immunological mechanisms in the pathogenesis of diabetic retinopathy. Semin Immunopathol (2008) 30(2):65-84.
49. Kern TS: Contribution of inflammatory processes to the development of the early stages of diabetic retinopathy. Exp Diabetes Res (2007) 2007:95103.
50. Böckmann S, Paegelow I: Kinins and kinin receptors: Importance for the activation of leukocytes. J Leukoc Biol (2000) 68(5):587-592.
51. 1 receptor and the chemokine CXCL5. J Immunol (2007) 179(7):4849-4856.
52. 1 receptors induces chemotaxis of human neutrophils. J Leukoc Biol (2006) 80(1):117-124.
53. Wedmore CV, Williams TJ: Control of vascular permeability by polymorphonuclear leukocytes in inflammation. Nature (1981) 289(5799):646-650. •• Provided the first evidence that neutrophils cooperate with endothelial cells in response to inflammatory agents such as C5a, FMLP, LTB4 and bradykinin to control the effux of fuid and macromolecules through the blood vessel wall that leads to tissue edema.
54. Bek T: Immunohistochemical characterization of retinal glial cell changes in areas of vascular occlusion secondary to diabetic retinopathy. Acta Ophthalmol Scand (1997) 75(4):388-392.
55. Zeng HY, Green WR, Tso MO: Microglial activation in human diabetic retinopathy. Arch Ophthalmol (2008) 126(2):227-232.
56. 2+ exchanger. J Neurosci (2007) 27(48):13065-13073.
57. 1 receptor attenuates cardiac inflammation and fibrosis during the development of experimental diabetic cardiomyopathy. Diabetes (2009) 58(6):1373-1381.